Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Systemic Cyclosporin A (CSA) and Mycophenolat Mofetil (MMF) as Prophylaxis of Immune Reactions after Allogenic High-risk Penetrating Keratoplasty
Sokolovska J.1, Reinhard T.2, Böhringer D.1, Spelsberg H.1, Sundmacher R.1
1Eye Hospital, Heinrich-Heine University, Düsseldorf
2Eye Hospital, Albert-Ludwigs-University, Freiburg
Purpose: Since 1987 485 patients undergoing high-risk penetrating keratoplasty received systemic CSA or MMF. Retrospectively, we evaluated efficacy and safety of these immunosupressives.
Method: 294 patients were treated postoperatively with systemic CSA for 12,5 + 11,5 months and 191 patients with MMF for 8,2 + 3,1 months. There was no statistically significant difference between the groups concerning patient age, patient gender, donor age, donor gender, organ culture period, graft diameter, HLA-matching and follow up period. Indications for surgery were: a history of previous keratoplasty or deep vascularization in 3 or 4 quadrants: 89 in the CSA group/ 90 in the MMF group; severe atopic dermatitis 67/10; limbal stem cell deficiency 103/35, glaucoma induced endothelial failure 30/25; Herpes-simplex-virus or Acanthamoeba keratitis 5/31.
Results: Three years postoperatively 92,2% of the grafts in the CSA group and 83,8% in the MMF group were free from immune reactions (Kaplan and Meier values, log-rank test, p>0,5). Clear graft survival was 85,5% in the CSA group versus 91,2% in the MMF group (Kaplan and Meier values, l